Analysis of factors predicting the efficacy of Imatinib in patients with Chronic Myeloid Leukemia: A retrospective analysis
Article Sidebar
Main Article Content
Abstract
Objective: Imatinib is a commonly used first generation tyrosine kinase inhibitor for patients with chronic myeloid leukemia (CML). The efficacy has been reported as very high even in recent studies.
Material and methods: A retrospective analysis was made of newly diagnosed CML patients treated with Imatinib as a first-line agent from January 2010 to January 2020. The patients were classified as those who obtained an adequate response and those for whom treatment was discontinued due to inadequate efficacy. The two groups were compared to analyze factors predicting the efficacy of the agent.
Results: Evaluation was made of a total of 47 CML patients, comprising 20 females (42.6%) and 27 males (57.4%) with a median age of 55 years. Imatinib was discontinued in 19 patients because of inadequate response, and 28 patients were still continuing the treatment at the end of median 33.3 months follow-up duration. At the end of follow-up, there were 44 survivors (93.6%), and 3 non-survivors (6.4%). Median Bcr-Abl (IS, %) at the time of diagnosis in patients with response was higher than patients in discontinued group (67.6 [0.0-291.4] vs 41.9 [0.0-208.5], p=0.022). All other disease and demographic characteristics were similar in both groups (p>0.05).
Conclusion: Almost 10 years of follow-up demonstrated that there is still an unmet need to determine factors predicting the response to Imatinib in CML patients. Larger population-based studies are required to specify patients with high risk at the time of diagnosis to monitor closely.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-09-23
Published 2022-09-23
References
Sawyers CL. Chronic myeloid leukemia. New England Journal of Medicine. 1999;340(17):1330-40. DOI: https://doi.org/10.1056/NEJM199904293401706
Society AC. Cancer facts & figures 2014: American Cancer Society; 2014.
Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123-7. DOI: https://doi.org/10.1002/cncr.26679
Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. American Society of Hematology; 2009. DOI: https://doi.org/10.1182/blood.V114.22.1126.1126
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine. 2003;348(11):994-1004. DOI: https://doi.org/10.1056/NEJMoa022457
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. American journal of hematology. 2018;93(3):442-59. DOI: https://doi.org/10.1002/ajh.25011
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine. 2017;376(10):917-27. DOI: https://doi.org/10.1056/NEJMoa1609324
Kantarjian H, Larson R, Guilhot F, Druker B. on Behalf of IRIS Study Group: Declining rates of adverse events (AEs), rare occurrence of serious AEs, and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia in chronic phase initially treated with imatinib in the international randomized study of interferon vs STI571 (IRIS). Blood. 2006;108. DOI: https://doi.org/10.1182/blood.V108.11.2136.2136
Akay FE, Koçyiğit B, Berfin T, ATLI Eİ, Volkan B, KIRKIZLAR HO. Retrospective analysis of chronic myeloid leukemia patients in Trakya university school of medicine. Turkish Medical Student Journal. 2019;6(3):70-4. DOI: https://doi.org/10.4274/tmsj.galenos.2019.06.03.01
Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014;28(10):1988-92. DOI: https://doi.org/10.1038/leu.2014.153
Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, et al. High BCR–ABL/GUSIS levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib. Clinical Cancer Research. 2017;23(23):7189-98. DOI: https://doi.org/10.1158/1078-0432.CCR-17-0962